0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Recombinant Hepatitis B Vaccine Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-11H7978
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Recombinant Hepatitis B Vaccine Market Insights and Forecast to 2028
BUY CHAPTERS

Global Recombinant Hepatitis B Vaccine Market Research Report 2025

Code: QYRE-Auto-11H7978
Report
July 2025
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Recombinant Hepatitis B Vaccine Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Recombinant Hepatitis B Vaccine Market

Recombinant Hepatitis B Vaccine Market

The global market for Recombinant Hepatitis B Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The hepatitis b vaccine is a vaccine against hepatitis b.That is, from hepatitis b virus carrier plasma isolation of hepatitis b surface antigen (HbsAg), after treatment and made.After second liver vaccine is inoculated, can stimulate immune system to produce protective antibody, this kind of antibody is in the humoral in the person, once second liver virus appears, antibody can act immediately, clear its, prevent infection, won"t harm liver, make human body had the immunity that prevents second liver thereby.Therefore, hepatitis b vaccine has become an indispensable umbrella in life.Prevention generally lasts for at least 12 years, so there is no need for anti-hbs surveillance or enhanced immunity in the general population.However, anti-hbs surveillance can be carried out on high-risk groups, such as anti-hbs <10mIU/ml, which can be given enhanced immunity.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Hepatitis B Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hepatitis B Vaccine.
The Recombinant Hepatitis B Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Hepatitis B Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Hepatitis B Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Recombinant Hepatitis B Vaccine Market Report

Report Metric Details
Report Name Recombinant Hepatitis B Vaccine Market
CAGR 5%
Segment by Type
  • 10mcg/ml
  • 10mcg/0.5ml
Segment by Application
  • Newborn
  • Primary School Students
  • Adult
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck, GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India, Johnson & Johnson, Hualan Biological Engineering, NCPC, China National Biotec Group, Dalian Hissen Bio-pharm, Beijing Tiantan Biological
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Recombinant Hepatitis B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Recombinant Hepatitis B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Recombinant Hepatitis B Vaccine Market report?

Ans: The main players in the Recombinant Hepatitis B Vaccine Market are Merck, GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India, Johnson & Johnson, Hualan Biological Engineering, NCPC, China National Biotec Group, Dalian Hissen Bio-pharm, Beijing Tiantan Biological

What are the Application segmentation covered in the Recombinant Hepatitis B Vaccine Market report?

Ans: The Applications covered in the Recombinant Hepatitis B Vaccine Market report are Newborn, Primary School Students, Adult

What are the Type segmentation covered in the Recombinant Hepatitis B Vaccine Market report?

Ans: The Types covered in the Recombinant Hepatitis B Vaccine Market report are 10mcg/ml, 10mcg/0.5ml

Recommended Reports

Vaccine Markets

Liver & Hepatitis

COVID-19 & Emerging

1 Recombinant Hepatitis B Vaccine Market Overview
1.1 Product Definition
1.2 Recombinant Hepatitis B Vaccine by Type
1.2.1 Global Recombinant Hepatitis B Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 10mcg/ml
1.2.3 10mcg/0.5ml
1.3 Recombinant Hepatitis B Vaccine by Application
1.3.1 Global Recombinant Hepatitis B Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Newborn
1.3.3 Primary School Students
1.3.4 Adult
1.4 Global Recombinant Hepatitis B Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant Hepatitis B Vaccine Revenue 2020-2031
1.4.2 Global Recombinant Hepatitis B Vaccine Sales 2020-2031
1.4.3 Global Recombinant Hepatitis B Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Recombinant Hepatitis B Vaccine Market Competition by Manufacturers
2.1 Global Recombinant Hepatitis B Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Recombinant Hepatitis B Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Recombinant Hepatitis B Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Recombinant Hepatitis B Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Date of Enter into This Industry
2.8 Global Recombinant Hepatitis B Vaccine Market Competitive Situation and Trends
2.8.1 Global Recombinant Hepatitis B Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Recombinant Hepatitis B Vaccine Players Market Share by Revenue
2.8.3 Global Recombinant Hepatitis B Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Recombinant Hepatitis B Vaccine Market Scenario by Region
3.1 Global Recombinant Hepatitis B Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Recombinant Hepatitis B Vaccine Sales by Region: 2020-2031
3.2.1 Global Recombinant Hepatitis B Vaccine Sales by Region: 2020-2025
3.2.2 Global Recombinant Hepatitis B Vaccine Sales by Region: 2026-2031
3.3 Global Recombinant Hepatitis B Vaccine Revenue by Region: 2020-2031
3.3.1 Global Recombinant Hepatitis B Vaccine Revenue by Region: 2020-2025
3.3.2 Global Recombinant Hepatitis B Vaccine Revenue by Region: 2026-2031
3.4 North America Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant Hepatitis B Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Recombinant Hepatitis B Vaccine Sales by Country (2020-2031)
3.4.3 North America Recombinant Hepatitis B Vaccine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant Hepatitis B Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Recombinant Hepatitis B Vaccine Sales by Country (2020-2031)
3.5.3 Europe Recombinant Hepatitis B Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Hepatitis B Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Recombinant Hepatitis B Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Recombinant Hepatitis B Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant Hepatitis B Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Recombinant Hepatitis B Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Recombinant Hepatitis B Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Hepatitis B Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Recombinant Hepatitis B Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Recombinant Hepatitis B Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Hepatitis B Vaccine Sales by Type (2020-2031)
4.1.1 Global Recombinant Hepatitis B Vaccine Sales by Type (2020-2025)
4.1.2 Global Recombinant Hepatitis B Vaccine Sales by Type (2026-2031)
4.1.3 Global Recombinant Hepatitis B Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Recombinant Hepatitis B Vaccine Revenue by Type (2020-2031)
4.2.1 Global Recombinant Hepatitis B Vaccine Revenue by Type (2020-2025)
4.2.2 Global Recombinant Hepatitis B Vaccine Revenue by Type (2026-2031)
4.2.3 Global Recombinant Hepatitis B Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Recombinant Hepatitis B Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Recombinant Hepatitis B Vaccine Sales by Application (2020-2031)
5.1.1 Global Recombinant Hepatitis B Vaccine Sales by Application (2020-2025)
5.1.2 Global Recombinant Hepatitis B Vaccine Sales by Application (2026-2031)
5.1.3 Global Recombinant Hepatitis B Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Recombinant Hepatitis B Vaccine Revenue by Application (2020-2031)
5.2.1 Global Recombinant Hepatitis B Vaccine Revenue by Application (2020-2025)
5.2.2 Global Recombinant Hepatitis B Vaccine Revenue by Application (2026-2031)
5.2.3 Global Recombinant Hepatitis B Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Recombinant Hepatitis B Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Recombinant Hepatitis B Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GlaxoSmithKline Plc
6.2.1 GlaxoSmithKline Plc Company Information
6.2.2 GlaxoSmithKline Plc Description and Business Overview
6.2.3 GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Product Portfolio
6.2.5 GlaxoSmithKline Plc Recent Developments/Updates
6.3 Pfizer Inc.
6.3.1 Pfizer Inc. Company Information
6.3.2 Pfizer Inc. Description and Business Overview
6.3.3 Pfizer Inc. Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Inc. Recombinant Hepatitis B Vaccine Product Portfolio
6.3.5 Pfizer Inc. Recent Developments/Updates
6.4 Sanofi Pasteur
6.4.1 Sanofi Pasteur Company Information
6.4.2 Sanofi Pasteur Description and Business Overview
6.4.3 Sanofi Pasteur Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Pasteur Recombinant Hepatitis B Vaccine Product Portfolio
6.4.5 Sanofi Pasteur Recent Developments/Updates
6.5 CSL Limited
6.5.1 CSL Limited Company Information
6.5.2 CSL Limited Description and Business Overview
6.5.3 CSL Limited Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 CSL Limited Recombinant Hepatitis B Vaccine Product Portfolio
6.5.5 CSL Limited Recent Developments/Updates
6.6 Emergent Biosolutions
6.6.1 Emergent Biosolutions Company Information
6.6.2 Emergent Biosolutions Description and Business Overview
6.6.3 Emergent Biosolutions Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Emergent Biosolutions Recombinant Hepatitis B Vaccine Product Portfolio
6.6.5 Emergent Biosolutions Recent Developments/Updates
6.7 Serum Institute of India
6.7.1 Serum Institute of India Company Information
6.7.2 Serum Institute of India Description and Business Overview
6.7.3 Serum Institute of India Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Serum Institute of India Recombinant Hepatitis B Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
6.8 Johnson & Johnson
6.8.1 Johnson & Johnson Company Information
6.8.2 Johnson & Johnson Description and Business Overview
6.8.3 Johnson & Johnson Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Johnson & Johnson Recombinant Hepatitis B Vaccine Product Portfolio
6.8.5 Johnson & Johnson Recent Developments/Updates
6.9 Hualan Biological Engineering
6.9.1 Hualan Biological Engineering Company Information
6.9.2 Hualan Biological Engineering Description and Business Overview
6.9.3 Hualan Biological Engineering Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Hualan Biological Engineering Recombinant Hepatitis B Vaccine Product Portfolio
6.9.5 Hualan Biological Engineering Recent Developments/Updates
6.10 NCPC
6.10.1 NCPC Company Information
6.10.2 NCPC Description and Business Overview
6.10.3 NCPC Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 NCPC Recombinant Hepatitis B Vaccine Product Portfolio
6.10.5 NCPC Recent Developments/Updates
6.11 China National Biotec Group
6.11.1 China National Biotec Group Company Information
6.11.2 China National Biotec Group Description and Business Overview
6.11.3 China National Biotec Group Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 China National Biotec Group Recombinant Hepatitis B Vaccine Product Portfolio
6.11.5 China National Biotec Group Recent Developments/Updates
6.12 Dalian Hissen Bio-pharm
6.12.1 Dalian Hissen Bio-pharm Company Information
6.12.2 Dalian Hissen Bio-pharm Description and Business Overview
6.12.3 Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Product Portfolio
6.12.5 Dalian Hissen Bio-pharm Recent Developments/Updates
6.13 Beijing Tiantan Biological
6.13.1 Beijing Tiantan Biological Company Information
6.13.2 Beijing Tiantan Biological Description and Business Overview
6.13.3 Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Product Portfolio
6.13.5 Beijing Tiantan Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Hepatitis B Vaccine Industry Chain Analysis
7.2 Recombinant Hepatitis B Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Hepatitis B Vaccine Production Mode & Process Analysis
7.4 Recombinant Hepatitis B Vaccine Sales and Marketing
7.4.1 Recombinant Hepatitis B Vaccine Sales Channels
7.4.2 Recombinant Hepatitis B Vaccine Distributors
7.5 Recombinant Hepatitis B Vaccine Customer Analysis
8 Recombinant Hepatitis B Vaccine Market Dynamics
8.1 Recombinant Hepatitis B Vaccine Industry Trends
8.2 Recombinant Hepatitis B Vaccine Market Drivers
8.3 Recombinant Hepatitis B Vaccine Market Challenges
8.4 Recombinant Hepatitis B Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Recombinant Hepatitis B Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Recombinant Hepatitis B Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Recombinant Hepatitis B Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Recombinant Hepatitis B Vaccine Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Recombinant Hepatitis B Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Recombinant Hepatitis B Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Recombinant Hepatitis B Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Recombinant Hepatitis B Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Recombinant Hepatitis B Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Hepatitis B Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Recombinant Hepatitis B Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Recombinant Hepatitis B Vaccine Sales by Region (2020-2025) & (K Units)
 Table 18. Global Recombinant Hepatitis B Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Recombinant Hepatitis B Vaccine Sales by Region (2026-2031) & (K Units)
 Table 20. Global Recombinant Hepatitis B Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Recombinant Hepatitis B Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Recombinant Hepatitis B Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Recombinant Hepatitis B Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Recombinant Hepatitis B Vaccine Sales by Country (2020-2025) & (K Units)
 Table 27. North America Recombinant Hepatitis B Vaccine Sales by Country (2026-2031) & (K Units)
 Table 28. North America Recombinant Hepatitis B Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Recombinant Hepatitis B Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Recombinant Hepatitis B Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Recombinant Hepatitis B Vaccine Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Recombinant Hepatitis B Vaccine Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Recombinant Hepatitis B Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Recombinant Hepatitis B Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Recombinant Hepatitis B Vaccine Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Recombinant Hepatitis B Vaccine Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Recombinant Hepatitis B Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Recombinant Hepatitis B Vaccine Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Recombinant Hepatitis B Vaccine Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Recombinant Hepatitis B Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Recombinant Hepatitis B Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Recombinant Hepatitis B Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Recombinant Hepatitis B Vaccine Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Recombinant Hepatitis B Vaccine Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Recombinant Hepatitis B Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Recombinant Hepatitis B Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Type (2020-2025)
 Table 51. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Type (2026-2031)
 Table 52. Global Recombinant Hepatitis B Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Recombinant Hepatitis B Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Application (2020-2025)
 Table 61. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Application (2026-2031)
 Table 62. Global Recombinant Hepatitis B Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Recombinant Hepatitis B Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Application (2026-2031)
 Table 70. Merck Company Information
 Table 71. Merck Description and Business Overview
 Table 72. Merck Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Merck Recombinant Hepatitis B Vaccine Product
 Table 74. Merck Recent Developments/Updates
 Table 75. GlaxoSmithKline Plc Company Information
 Table 76. GlaxoSmithKline Plc Description and Business Overview
 Table 77. GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Product
 Table 79. GlaxoSmithKline Plc Recent Developments/Updates
 Table 80. Pfizer Inc. Company Information
 Table 81. Pfizer Inc. Description and Business Overview
 Table 82. Pfizer Inc. Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer Inc. Recombinant Hepatitis B Vaccine Product
 Table 84. Pfizer Inc. Recent Developments/Updates
 Table 85. Sanofi Pasteur Company Information
 Table 86. Sanofi Pasteur Description and Business Overview
 Table 87. Sanofi Pasteur Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Sanofi Pasteur Recombinant Hepatitis B Vaccine Product
 Table 89. Sanofi Pasteur Recent Developments/Updates
 Table 90. CSL Limited Company Information
 Table 91. CSL Limited Description and Business Overview
 Table 92. CSL Limited Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. CSL Limited Recombinant Hepatitis B Vaccine Product
 Table 94. CSL Limited Recent Developments/Updates
 Table 95. Emergent Biosolutions Company Information
 Table 96. Emergent Biosolutions Description and Business Overview
 Table 97. Emergent Biosolutions Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Emergent Biosolutions Recombinant Hepatitis B Vaccine Product
 Table 99. Emergent Biosolutions Recent Developments/Updates
 Table 100. Serum Institute of India Company Information
 Table 101. Serum Institute of India Description and Business Overview
 Table 102. Serum Institute of India Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Serum Institute of India Recombinant Hepatitis B Vaccine Product
 Table 104. Serum Institute of India Recent Developments/Updates
 Table 105. Johnson & Johnson Company Information
 Table 106. Johnson & Johnson Description and Business Overview
 Table 107. Johnson & Johnson Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Johnson & Johnson Recombinant Hepatitis B Vaccine Product
 Table 109. Johnson & Johnson Recent Developments/Updates
 Table 110. Hualan Biological Engineering Company Information
 Table 111. Hualan Biological Engineering Description and Business Overview
 Table 112. Hualan Biological Engineering Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Hualan Biological Engineering Recombinant Hepatitis B Vaccine Product
 Table 114. Hualan Biological Engineering Recent Developments/Updates
 Table 115. NCPC Company Information
 Table 116. NCPC Description and Business Overview
 Table 117. NCPC Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. NCPC Recombinant Hepatitis B Vaccine Product
 Table 119. NCPC Recent Developments/Updates
 Table 120. China National Biotec Group Company Information
 Table 121. China National Biotec Group Description and Business Overview
 Table 122. China National Biotec Group Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. China National Biotec Group Recombinant Hepatitis B Vaccine Product
 Table 124. China National Biotec Group Recent Developments/Updates
 Table 125. Dalian Hissen Bio-pharm Company Information
 Table 126. Dalian Hissen Bio-pharm Description and Business Overview
 Table 127. Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Product
 Table 129. Dalian Hissen Bio-pharm Recent Developments/Updates
 Table 130. Beijing Tiantan Biological Company Information
 Table 131. Beijing Tiantan Biological Description and Business Overview
 Table 132. Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Product
 Table 134. Beijing Tiantan Biological Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Recombinant Hepatitis B Vaccine Distributors List
 Table 138. Recombinant Hepatitis B Vaccine Customers List
 Table 139. Recombinant Hepatitis B Vaccine Market Trends
 Table 140. Recombinant Hepatitis B Vaccine Market Drivers
 Table 141. Recombinant Hepatitis B Vaccine Market Challenges
 Table 142. Recombinant Hepatitis B Vaccine Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Recombinant Hepatitis B Vaccine
 Figure 2. Global Recombinant Hepatitis B Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Recombinant Hepatitis B Vaccine Market Share by Type: 2024 & 2031
 Figure 4. 10mcg/ml Product Picture
 Figure 5. 10mcg/0.5ml Product Picture
 Figure 6. Global Recombinant Hepatitis B Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Recombinant Hepatitis B Vaccine Market Share by Application: 2024 & 2031
 Figure 8. Newborn
 Figure 9. Primary School Students
 Figure 10. Adult
 Figure 11. Global Recombinant Hepatitis B Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Recombinant Hepatitis B Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Recombinant Hepatitis B Vaccine Sales (2020-2031) & (K Units)
 Figure 14. Global Recombinant Hepatitis B Vaccine Average Price (US$/Unit) & (2020-2031)
 Figure 15. Recombinant Hepatitis B Vaccine Report Years Considered
 Figure 16. Recombinant Hepatitis B Vaccine Sales Share by Manufacturers in 2024
 Figure 17. Global Recombinant Hepatitis B Vaccine Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Recombinant Hepatitis B Vaccine Players: Market Share by Revenue in Recombinant Hepatitis B Vaccine in 2024
 Figure 19. Recombinant Hepatitis B Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Recombinant Hepatitis B Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Recombinant Hepatitis B Vaccine Sales Market Share by Country (2020-2031)
 Figure 22. North America Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Recombinant Hepatitis B Vaccine Sales Market Share by Country (2020-2031)
 Figure 26. Europe Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Recombinant Hepatitis B Vaccine Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Recombinant Hepatitis B Vaccine Revenue Market Share by Region (2020-2031)
 Figure 34. China Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Taiwan Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Philippines Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Recombinant Hepatitis B Vaccine Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Recombinant Hepatitis B Vaccine Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Recombinant Hepatitis B Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Recombinant Hepatitis B Vaccine by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Recombinant Hepatitis B Vaccine by Type (2020-2031)
 Figure 56. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Recombinant Hepatitis B Vaccine by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Recombinant Hepatitis B Vaccine by Application (2020-2031)
 Figure 59. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Application (2020-2031)
 Figure 60. Recombinant Hepatitis B Vaccine Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS